Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Haematologica
; 109(1): 245-255, 2024 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439329
3.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528035
4.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
5.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica
; 108(3): 833-842, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200419
6.
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
Haematologica
; 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37981892
7.
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort.
Hematol Oncol
; 41(1): 128-138, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265128
8.
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.
Hematol Oncol
; 40(5): 846-856, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35854643
9.
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.
Br J Haematol
; 195(3): 371-377, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34272724
10.
The role of autologous stem-cell transplantation in multiple myeloma in 2021.
Curr Opin Oncol
; 33(6): 642-647, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34419954
11.
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Haematologica
; 106(4): 1079-1085, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107329
12.
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Ann Hematol
; 100(2): 437-443, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392702
13.
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Haematologica
; 105(4): 1074-1080, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31248973
14.
Is there still a role for stem cell transplantation in multiple myeloma?
Cancer
; 125(15): 2534-2543, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985927
15.
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Cancer
; 125(3): 416-423, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30332496
16.
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.
Haematologica
; 104(8): 1640-1647, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30733270
17.
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Blood
; 127(9): 1102-8, 2016 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26729895
18.
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Blood
; 122(16): 2799-806, 2013 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23954889
19.
Redefining the treatment paradigm for multiple myeloma.
Lancet Oncol
; 20(6): 743-744, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097404
20.
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab.
Cytometry A
; 95(4): 416-418, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30908843